07-22-02

福出

Docket No. 54

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Bowdish et al.

Serial No:

10/006,593

Examiner:

Unassigned

Filed:

December 5, 2001

Group:

Unassigned

For:

Rationally Designed Antibodies

Assistant Commissioner for Patents Washington, D.C. 20231

CERTIFICATE OF MAILING

Date of Deposit: July 19, 2002 I hereby certify that the following:

- [x] This Certificate of Mailing
- [x] Information Disclosure Statement
- [x] 1449 Form
- [x] ___ (78) Cited References
- [x] Return postcard

are being deposited with the United States Postal Service first-class mail on the Date of Deposit indicated above in an envelope addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

Mark Farber C/0 Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06419

Docket:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bowdish et al.

Serial No: 10/006,593

Examiner: Unassigned

Filed:

December 5, 2001

Group: Unassigned

For:

Rationally Designed Antibodies

Assistant Commissioner of Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

In accordance with Applicant's duty of disclosure under 37 C.F.R §1.56, Applicants submit the enclosed reference for the Examiner's consideration.

It is respectfully requested that the reference(s) submitted with Form PTO-1449 be considered during Examination of the above-identified application and made of record therein. A copy of the reference(s) is/are enclosed. This submission is believed to be in compliance with 37 C.F.R. §1.97 and 37 C.F.R. §1.98.

The citation of the listed item(s) is not a representation that it constitutes a complete or exhaustive listing of prior art or that it constitutes prior art. The item(s) listed is/are submitted in good faith, but is/are not intended to substitute for the Examiner's search. It is hoped, however, that in addition to apprising the Examiner, it will assist the Examiner in identifying fields of search and in making as full and complete a search as possible.

The filing of this information disclosure statement is not an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

TECH CENTER 1800/2900

- () This information disclosure statement is being filed within three (3) months of the filing date of this application.
- () This information disclosure statement is being filed within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R.§ 1.491 in an international application.
- (x) To the best of Applicant(s) knowledge, this information disclosure statement is being filed before the date of mailing of a first Office Action in connection with this case.
- () Enclosed is a certificate under 37 C.F.R. §1.97 (e)(i).
- () Enclosed is a petition under 37 C.F.R. §1.97 (d)
- () Please charge the petition fee of \$130.00 required under 37 C.F.R. \$1.17 (i)(1) to Deposit Account No. 01-0483.
- () As set forth in 37 C.F.R. §1.97 (c), to the best of Applicant(s) knowledge, this information disclosure statement is being filed before either the mailing of a final action under 37 C.F.R.§1.113 or the mailing of a notice of allowance under 37 C.F.R. §1.113, and is accompanied by the \$220.00 fee as provided for in 37 C.F.R. §1.17(p).
- () Please charge the \$220.00 fee required by 37 C.F.R. §1.17(p) to Deposit Account No. <u>01-0483</u>.
- (X) Please charge any deficiency as well as any other fee(s) which may become due under 37 C.F.R. §1.16 and/or 37 C.F.R. §1.17 at any time during the pendency of this application, or credit any overpayment of such fee(s) to Deposit Account 01-0483. Also, in the event any extensions of time for responding are required for the pending application(s), please treat this paper as a petition to extend time as required and charge Deposit Account No. 01-0483 therefor. TWO COPIES OF THIS SHEET ARE ENCLOSED.

Early and favorable consideration of the case is respectfully requested.

Dated: 7-17-02

Mark Farber

Registration No. 34,159 Attorney for the Applicants

Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410 (203) 271-8319

Form PTC								PARTMENT OF MARK	ATTY. D	OCKET NO.				ERIAL .0 70 06,		<u> </u>
I S	TAT	EMI	INE	B	Y A	PP	LIC	SURE CANT ecessary)		ATTATU	10 #9			OH CENTER	JUL 2	
(OSE)	5	700		<u>j</u>	:LS	<u> </u>	<u> </u>	ecessary)		et al.		1		600/29		
Anr	10		ا لئي لان						FILING Decembe	DATE er 5, 2001			GRO 1645	Art	Uni	<u>رن</u>
W.	III	ane!	31					ť	S. PATENT DOC	UMENT						
EXAMINER INITIALS				CUI				DATE	NAMI		CLASS	SUB	CLASS	FILIN APPRO	IF	
ZG	\Box	4 6	-	2	+	┷	4	2/10/87	Moore et al.		530	388	3*			_
	-+	4 8	+-	Ť	+-	<u> </u>	-	3/28/89	Boss et al.		435	4 8				
	-	5 1	+	Ť	+		1-1	5/26/92	Capon et al.		536	137				
		5 4 5 5	-	-	+	3	10	6/27/95	Capon et al.	1	530 435	350 240				—
		5 8	+-	+	+	<u>3</u>	5 3	12/16/97 2/23/99	Robinson et al Tsujimoto et a		435	69	•			
+	_	5 8	+	-		-	-	3/2/99	Crowe et al.	14.	435	69		 		—
		5 9	_	_	+-	5		7/6/99	Sytkowski		514	18.	• -			—
- Ye - 	T	5 9	+	2	5	4	6	8/3/99	Barrett et al.		314	144				_
M		6 0) 4	0	1	3	6	3/21/00	Garrard et al.		435	-5-				_
·			r	DOC NU	UMI MBI		ŗ	DATE	COU	NTRY	LASS	SUBCI	LASS	TRANSI	LATIC	N(
		\sqcup	-	\dashv	\dashv	+	+	<u> </u>	<u></u>						<u> </u>	
-		Н	\dashv	+	\dashv	+	+		 	····		*			+	—
		Н	\dashv	\dashv	-	+		_			-		_			
		H	┪	十	\dashv	†	\top						-		†	—
	0	THE	ER.	DOC	CUM	EN	TS	(Including	Author, Title	, Date, Per	tinent	Pages	, Etc	c.)		
			St	ev	en nt	E.	Cv	virla et,al	l. "Peptide Ago Cytokine". Jun	nist of the	Thromb	opoie	etin	Recept		
			Er fr	kk	i F	ag	re I	Display Lib	"Selection of orary". Septemb o.27, pp. 20205	er 25,1993.					grin	
			Er Di	kk ff	i K ere	oi nt	vur R	nent et,al ing Sizes:I	"Phage Librar Ligand Specific March 1995 pp.	ies Display ities of th						
			Ju Ra	di nd	th om	M. Ph	He	ealy et,al.	"Peptide Liga Libraries". Jan	nds for Int						
EXAMINER					-				DATE CONSIDER	ED					•	
MPEP 609	; D	raw	1	ine	e t	hr	oug	h citation	ered, whether of if not in contact ation to application	formance and						<u> </u>
CODY OI	-111	۱ د	<u>. U L</u>	V	۷ _ 		.167	C COMMUNIC	acton to applic							

Form DEO	1.	1.4.0			<u>-</u>			VED	ADMMENT OF	A TOTAL DO	CVET NO			l e	ERIA P I	NIO	=
COMMERCE									ARTMENT OF	ATTY. DO	CKET NO.				0/0		
OFFICE	. F.	41E	iIN .	. д	.41	, 11	· CA.	וטע	MARK	54				1			
OLLICE																JÜL	
IN	VFO	RM	ΑТ	ION	J]	DIS	CI	os	URE							7	:
									ANT						<u>□ae</u>	₹	
-	-														CENTER 1800/290	9	
Mise se	ve	a)	\ 5	shee	et	.s :	if	n	ecessary)						<u></u>	2002	
		•	62/	\						APPLICAN	T				9	200	ſ
1	์ ช	Ø	ų	À						Bowdish	et al.				. E		F
1111 18	9 "		į	į.													2
12. 30°			٦	7						FILING D	ATE			L	UP Art	Uni	Ե :
		, <	,							_				1645	i		
V(V) 3	<u>. C</u>	136	_		_					December	5, 2001			i			
~~~	EX.								U	.S. PATENT DOCUM	MENT						
EXAMINER								Π							FILING	G DA	ΓE
INITIALS				OCU			•	١	DATE	NAME		CLASS	SUE	CLASS		F	
	$\perp$	_	_	NUM	_	_							↓		APPROI	PRIA'	ſΕ
UN		<del></del>	圵	9 8	<u> </u>				1/28/97	Williams et al.		373		.1-	<u> </u>		
		•		7 2	_	1	9	7	1/9/01	McCafferty et a	al.	5/30	38	7.3			
	_	_	廴	6 9	廴	1	0		10/19/99	McCafferty et a	al	530	3 8	7.3			
		5 2	2	2 3	3	4	0		6/29/93	Ladner et al.		435	69	.1			
		5 8	3	3 7	7	5	0	0	11/17/98	Ladner et al.		<u>.</u> 435	<b>-6</b> 5	.7			
¥		5 !	5	7 1	Ц	6	9	8	11/5/96	Ladner et al.		<b>48</b> 5	6\4	.7			
LPA		5	7	5 0	ΣŢ	3	7	3	5/12/98	Garrard et al.		435	€9	<del>-4</del>			
				DOC		MEI IBEI			DATE	EIGN PATENT DOCU		LASS	SUBC	LASS	TRANSL	ATIC	N
		Н		ТТ		Т	T	Т			*					+	
<del> </del>		Н		+	$\vdash$	十	H	+				<del></del>				┼─	
		Н		+	$\overline{}$	┿	┝	╅	<del> </del>							+	
<del></del>		Н		╁╾┧		┿	<del> </del>	┿	+			<del>-                                     </del>				╁	
		╌┤		$\vdash$	_	+	⊢	+	+			<del></del>				<del> </del>	
				닏	_			<u></u>	(T 1 - 1	1	D-1 D	<u> </u>		- 5	_ \		_
<del></del>	0	T.HT	_		_					Author, Title,							_
										. "Regonition of	_	_					
			+							AM. Chem. Soc.,						1005	
[										. "Human autoant			OT I	DNA".	march	T 3 3 5	٠.
		<del> </del>	-							. USA. Vol 92, p			+	2222	, ,,,, a.b	+	
1										id and efficient . January 1985.							
			Ŀ	op.	48	38-	49	2.									
										ynthetic Antiboo						fini	.ty
1										thods in Molecul	lar Biolog	, Vol.51	: A1	ntiboo	ły		
		L_	Ŀ	Eng.	<u>ir</u>	1ee	ri	ng	Protcols.	Pp.329-342.							
EXAMINER										DATE CONSIDERE	D						
EXAMINED.	. т	ni	- ;	a 1	<u> </u>	<del>-</del>	i +	- + e	ion consid	ered, whether or	r not gita	tion is	in	confo	rmance	wi+1	
										if not in confo							•
,	٠, ٢	_ 41			. –			· uy		. II HOU III COIIIC	ormance an			acrea			

copy of this form with next communication to applicant.

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

Sci. USA Biochemistry. Vol. 88, pp. 7978-7982.

EXAMINER

on phage surfaces: The gene III site". September 1991. Proc. Natl. Acad.

(Form PTO-1449 [6-4])

Form Porm Porm Port Port Port Port Port Port Port Port	CE P							PARTMENT OF EMARK	ATTY. DOCKET NO.			1	ERIAL N .0/006,5	
								SURE CANT					CENT	
(Use_	seve	ra:	1 s	she	ets	i	.f r	necessary)				1	<b>m</b> 80	m
OIF			\						APPLICANT Bowdish et al.				8 2002t	N.
ML 19	2001		13. T.						FILING DATE December 5, 2001			G <b>&amp;</b> 16 <b>€</b>	up ärt	Ü
TO TOP	DEME							Ü	.S. PATENT DOCUMENT					
EXAMINER INITIALS	1 1							DATE	NAME	CLASS	SUB	CLASS	FILING II APPROP	ਵ
M	1	DOCUMENT DAY NUMBER  6 0 0 8 0 2 3 12/28 5 2 6 0 4 1 7 11/9/		12/28/99	Opper et al.	435	69	<del>.</del> 7						
M				11/9/93	Grant et al.	530	35.							
ih		6 0 0 8 0 2 3 5 2 6 0 4 1 7			6 6	1/14/97	McDonald	424	-85	<b>.</b> 1				
				DOC NT	CUM			DATE	COUNTRY	LASS	SUBCI	LASS	TRANSL	ATION
		┝	⊢	$\vdash$	_	Н	$\dashv$							
		H	Н	Н		$\dashv$								
		┝	⊢	Н	-	$\vdash$	$\dashv$							
		┝	┢	$\vdash$		$\dashv$	$\dashv$							
	0	TН	ER	DO		MEN	UTS	(Including	Author, Title, Date, Pe	rtinent	Pages	Et.	~ . )	
			F A	obe ffi	ert ni	E ty	. H	lawkins et,a April,1992	al. "Selection of Phage J. Mol. Biol. 226, pp.8 al. "Recombinant anti-si	Antibodi 89-896.	es by	y Bin	ding	iable
			f	rac	me	nt	ar	tibody". 19	994. Eur. J. Biochem. 221	, pp.151	-157	•		
			ď		er				"Properties of a single-cides". 1995. Protein Engi					
									l. "Human Antibodies from unology, Vol.57, pp.191-2		toria	al Li	braries	3".
EXAMINE	R								DATE CONSIDERED					
MPEP 60	9; D	ra	W	lin	e i	thi	rou	gh citation	lered, whether or not cit if not in conformance a ation to applicant.					

Form COMME OFFIC	RCE I							ARTMENT OF MARK	A 5	TTY. DOCKET N 4	10.		1	SERIAL 10/006	,593
(IIse	STA	TEM	EN'	тв	Y A	APF	PLIC	SURE CANT ecessary)						CH CENTE	° inir EUCHI
- (OSE	٠٬٠٠	9 T	ur.	TO BO				ceessary	В	PPLICANT owdish et al. ILING DATE			GRO	1600 Art	
27	m,			A CAR						ecember 5, 20	01		164	900	
		Ans	Mic					U	.S. PATEI	NT DOCUMENT					
EXAMINI INITIAI				OCUI				DATE		NAME		CLASS	SUBCLAS	S	NG DATE IF OPRIATE
	$\dashv$	+	+	+	╁	╀	${f H}$			·			<del> </del>	<del>                                     </del>	
		$\mp$	1	Ŧ	F	F	$\Box$								
		$\perp$	1	丰	T	$ \perp$	Ħ								
<del></del>	<u> </u>				<u> </u>	<u> </u>	<u> </u>	FOR	EIGN PATI	ENT DOCUMENTS			<u> </u>		
				DOC NU	UMI MBI		<del></del>	DATE		COUNTRY		LASS	SUBCLASS	TRANS	LATION
				П	·T	$\Box$	$\Box$		i 						+
		$\bot$			$\exists$	$\mp$	干								
		$\bot$			$\Rightarrow$	#	#								
		<u></u>	ER	DOC	<u> </u> Mוזי	<u> </u>	<u></u>	(Including	Author	Title, Date,	Pert	inent 1	Pages Et	c )	
			R A	obe: ffi	rt nit	E. ty"	. На ′. А	wkins et,a pril,1992.	l. "Sel J. Mol.	ection of Pha Biol. 226, p	ge Ar p.889	ntibodi 9-896.	es by Bir	nding	
			A f:	lexa ragi	anc mer	der at	: A. ant	Kortt et, ibody". 19	al. "Rece 94. Eur.	ombinant anti J. Biochem.	-sial 221,	lidase pp.151	single-ch -157.	ıain va	ariable
			K.	aija	a P	Alf	tha	ın et,al. "	Properti	es of a single 95. Protein E	e-cha	ain ant	ibody cor		
			D	enn:						Antibodies f			torial Li	.brarie	es".
EXAMIN	ER	<del></del> .		<u></u> -	, ,	<u>-                                    </u>	anc	CO III INUIU		NSIDERED	1-200	, .			
MPEP 6	09; I	Ora	w ]	line	e t	hr	oug:	h citation	if not i	ether or not on the conformance applicant.					
													····		

Form PTO- COMMERCE						ARTMENT OF	ATTY. DOCKET NO.				ERIAI		
OFFICE							54				9		=
			ON I									JUL 2	[ (
Use ev	era	l sl	neet	s i	f ne	ecessary)					អាច ⊐បៈ	&D	
1	\						APPLICANT				<u> </u>	-	<
III 19 TOTA	<u>\$</u>						Bowdish et al.				600/2	2002	M
	j Ž						FILING DATE	•			A ₁	t Ur	de L
Cara Official							December 5, 2001						
This has						υ.	.S. PATENT DOCUMENT						
EXAMINER INITIALS			CUMI			DATE	NAME	CLASS	SUB	CLASS	3	ING I IF ROPRI	
	$\vdash$	$\frac{1}{1}$	I	<u> </u>	П						APP	KOPKI	LAT
	П		П										
	H	+	$\vdash$		$\vdash\vdash$		······································	ļ	-		-		
	$\vdash$	+	╁╌┼	+	$\vdash$		1-1-0-1						
						FORE	EIGN PATENT DOCUMENTS				1		
<del></del>	_					1 1		<del>-    </del>		T	TRAN	CT AT	TON
			OCUI			DATE	COUNTRY	LASS	SUBCI	LASS	IKAN	SLAI	101
			IVOI1.	DEK						-			
		П		П					****				
<del></del>	-	$\vdash$	+	╁┼	- -	-		$\rightarrow$	-				
	+	H	+-	╁┼	+		***					+	
	+	TT	$\dashv$	tt	+							+	_
	ОТН	ER 1	DOCU	MEN'	ГS	(Including	Author, Title, Date, Per	tinent	Pages	, Et	c.)		
		Ir	ene	Μ.	Lan	g et,al. "I	Purification of Storage (	Granule	Proti	len-2	3". N	loven	ube
	$\vdash$	DO	n L	90. Si	eae	letal "	logical Chemistry. Vol. 2 Isolation of cell surface	2/1, No.	4/, p	op.30	126-3	0135	<u>) .                                    </u>
							display and magnetically						ıaı
					ons	in immunol	hematology". 1997, J. of	Immunol	Logica	al Me	thods	, 20	)6
			.73-			£ 1 . 1 . 1							
		J J O An	nn c tibo	ae K adie	rui s f	rom a Semi	Leucine zipper Dimerized -synthetic Antibody Phage	Bivaler Dienla	nt and	d Bis	pecit " Ma	ic s	3CF
		29	,199	96,	The	J. of Bio	logical Chemistry, Vol.27	71, No.1	13, pr	5.763	0-763	4.	
		Pe	ter	Pac	k e	t,al. "Min	iantibodies: Use of Amphi	pathic	Helic	es I	o Pro	duce	•
							nked Dimeric Fv Fragments						
			84.	ricn	1a	coll". Febi	ruary 18,1992, Biochemist	ry, Vol	31,	No.6	, pp.	1579	<del>}</del> —
EXAMINER	-		<b>:</b>				DATE CONSIDERED						
T373377	<del>- :</del>		,				ered, whether or not cita		<del>.</del>		<del></del>		

Form I COMMER OFFICE	RCE							ENT OF		ATTY.	DOCKET	NO.				1	ERIAL .0/006	
(IIco	STA	TEM	ENT	BY	ΑP	PLI	SURE CANT	arv)									TECH CENTER 18 AFT	בּ <u>ה</u>
(036)	nit i	- L	11.00 M		3 .	11. 1	iecess	ary	<u> </u>	APPLI	CANT							$\frac{1}{2}$
	,									Bowdi	sh et a	1.					<b>30</b>	
( J	UL 19	300	ين الله							FILIN	IG DATE				<u> </u>	GR@	DEP Are	Unit:
			<u>.</u> 57					_		Decen	ıber 5 ,	2001					3	<u> </u>
		UE)	deil's				·	U	.S. PA	TENT D	OCUMENT							
EXAMINE INITIAL			DOC	UME MBE		•	DZ	ATE		N.	AME		CLA	SS	SUBC	LASS		IG DATE IF PRIATE
					$\perp$													
	+	+	++	+	+													
	+		+	+	+	+												
							I	FOR	EIGN P	ATENT	DOCUMENT	rs					<u> </u>	
				IUMI CUI			]	DATE		С	OUNTRY		LA	SS S	UBCL	ASS	TRANS:	LATION
		╁		Т		П	+		1					╁		-+		
								-		100								
				_										Ţ				
-		+	$\vdash$	╀	_	$\vdash \vdash$	<u> </u>		<del> </del>				_	$\bot$			-	
<u></u>	-		ת פפ		ME	איזייכ	(Troi	ludina	Author	r mit	le, Date	Dowl	-inon	- D	200	E+.	~ \	
	_		Phi	lip	q	Hol	liger	et,al		ineeri	ng bispe							
		Н									n of a 1	Bispec	ific	Ant	ibod	v Bv	The U	Jse Of
			Lei	cin	ıe	Zip 155	pers"	. Marc	h 1,19	92, Th	e J. of	Immun	ology	, v	01,1	48,	No.5,	
		1	Bae	k K	im	ı et	,al.	"Dimer	izatio	n of a	Specif	ic DNA	-Bind	ing	Pro	tien	on th	ie
		$\vdash$									55, pp.2 erichia			cci	on 5:	- ha	roda+	ion of
											gment" I							
			Wil	lia	m	J.v	an He	eckere	n et,a	1. "Ro	le of th	ne con	serve	d l	euci	nes .	in the	:
											of yeast		". Ju	ne	12,19	992,	Nucle	eic
EXAMIN	ΞR	Щ.	AC1	us	ке	sea	rcn,	vo1.20	1	<u>4, pp.</u> CONSID	3721-372 ERED	44.		-				
										-011010								
EXAMIN	ER:	Ini	tial	if	C:	ita	cion c	consid	ered, v	whethe	r or not	citat	cion :	is i	n cc	nfor	mance	with
MPEP 60	09;	Drav	w li	ne	th:	roug	gh cit	ation	if not	in c	onforman	ce and	not	cor	nside	ered.	Incl	ude
copy of	t th	1S :	torm	Wi	th	nez	kt_com	munic	ation t	co app	licant.							

Form PTO-144 COMMERCE PAT				PARTMENT OF EMARK				SERIAL NO. 10/006,593	
OFFICE INFOR					54			JUL JUL	11 11
STATE (Use severa								JUL JUL	$\tilde{\tilde{\Gamma}}$
THE JOYES					APPLICANT Bowdish et al.			2 9 20 TER 1600	
19 mm 5					FILING DATE			TP AR UN	
Property of the second				IJ	December 5, 2001  .S. PATENT DOCUMENT				<u>/</u>
EXAMINER INITIALS		CUME:		DATE	NAME	CLASS	SUBCLASS	FILING DA IF APPROPRIA	
	11/	I I					<del>                                     </del>	ATTROTAL	
					The Continue of the Continue o				
		·		FOR	EIGN PATENT DOCUMENTS			1	
		OCUM NUMB		DATE	COUNTRY	LASS	SUBCLASS	TRANSLATIO	ON
		$\Box$							
	$\Box$	力							
-	++	+	+-		<u>, , , , , , , , , , , , , , , , , , , </u>				
OTI					Author, Title, Date, Per				
	Re Do:	gula main	tory ". (:	Protein NTR 1994) J. Mol	The major Dimerization De C from Enteric Bacteria I . Biol. Vol.241, pp.233-2	Lie in It 245.	cs Carbo	cy-terminal	-
	Di	mer	in So	olution, wit	g et,al. "Gin Invertase of h the Domain for Dimeriza ) Biochemistry Vol.34, pp	ation in	the N-Te		t
	Pa in Di	ola Dim meri	Gall: erzat zatio	inari et,al. tion of the on Trap". Ju	"Localization of a 34-Ar Herpes Simplex Virus Type ne 1994, J. of Virology,	mino-Acio 1 ICP4 Vol.68,	d Segment Ploypept No.6, pr	ide by a 0.3809-3820	).
	Mu	tase	fron		"A Small, Thermosable, ar n Methanococcu jannaschii				.e
EXAMINER					DATE CONSIDERED				
MPEP 609; Dra	aw li	ine t	hrou	gh citation	ered, whether or not cita if not in conformance an ation to applicant.				h

OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)  APPLICANT Bowdish et al.  FILING DATE December 5, 2001  U.S. PATENT DOCUMENT	Form PTO-						ARTMENT OF	ATTY. DOCKET NO.			SERIAI 10/00		
APPLICANT Bowdish et al.  FILING DATE December 5, 2001  U.S. PATENT DOCUMENT  EXAMINER NUMBER  DOCUMENT NUMBER  TRANSLATIO APPROPRIATI DOCUMENTS  TRANSLATIO APPROPRIATI DOCUMENTS  TRANSLATIO APPROPRIATI DOCUMENTS  TRANSLATIO APPROPRIATI DOCUMENTS  TRANSLATIO APPROPRIATI		LWI	121/1	MIND	11	KADEI	MANIX	54			10,00	0,35.	•
APPLICANT Bowdish et al.  FILING DATE December 5, 2001  U.S. PATENT DOCUMENT  EXAMINER NUMBER  DOCUMENT NUMBER  TRANSLATIO APPROPRIATI DOCUMENTS  TRANSLATIO APPROPRIATI DOCUMENTS  TRANSLATIO APPROPRIATI DOCUMENTS  TRANSLATIO APPROPRIATI DOCUMENTS  TRANSLATIO APPROPRIATI	TNIC	ים	ar a m T	ONT	)TC	יכו ספ	יםחווי						
APPLICANT Bowdish et al.  FILING DATE December 5, 2001  U.S. PATENT DOCUMENT  EXAMINER NUMBER  DOCUMENT NUMBER  TRANSLATIO APPROPRIATI DOCUMENTS  TRANSLATIO APPROPRIATI DOCUMENTS  TRANSLATIO APPROPRIATI DOCUMENTS  TRANSLATIO APPROPRIATI DOCUMENTS  TRANSLATIO APPROPRIATI	CM3												
APPLICANT Bowdish et al.  FILING DATE December 5, 2001  U.S. PATENT DOCUMENT  NUMBER  DOCUMENT NUMBER  DOCUMENT NUMBER  DOCUMENT NUMBER  DOCUMENT NUMBER  DOCUMENT NUMBER  DOCUMENT NUMBER  DOCUMENT NUMBER  DOCUMENT NUMBER  DOCUMENT NUMBER  DOCUMENT NUMBER  DOCUMENT NUMBER  DOCUMENT NUMBER  DOCUMENT NUMBER  DOCUMENT NUMBER  DOCUMENT NUMBER  DOCUMENT NUMBER  DOCUMENT NUMBER  DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  Gavin MacReath et,al. "Redesigning Enzyme Topology by Directed Evolution". March 20,1998, Science. Vol.279, pp.1958-1961.  Paul Carter et,al. "High Level Escherichia Coli Expression and Production of a Bivalent Humanized Antibody Fragment". February 1992, BIO/TECHNOLOGY Vol.10, pp.163-167.  Iphigenia Leonidou Koumenis et,al. "Modulating pharmacokinetics of an anti interleuken-8F(ab')2 by amine-specific PEGylation with preserved bioactivity". International J. of Pharmaceutics (2000), Vol.198, pp.83-95. Marc Better et,al. "Potent anti-COS ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2". January 1993, Proc. Natl, Acad. Sci. USA, Vol.90, pp.457-461, Immunology.  DATE CONSIDERED											10	د	İ
Bowdish et al.  FILING DATE December 5, 2001  U.S. PATENT DOCUMENT NUMBER  DOCUMENT NUMBER  FOREIGN PATENT DOCUMENT  OTHER DOCUMENTS  OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  Gavin MacBeath et, al. "Redesigning Enzyme Topology by Directed Evolution". March 20,1998, Science. Vol.279, pp.1958-1961.  Paul Carter et, al. "High Level Escherichia Coli Expression and Production of a Bivalent Humanized Antibody Fragment". February 1992, BIO/TECHNOLOGY Vol.10, pp.163-167.  Iphigenia Leonidou Koumenis et, al. "Modulating pharmacokinetics of an anti interleuken-8F(ab')2 by amine-specific PEGylation with preserved bioactivity". International J. of Pharmaceutics (2000), Vol.198, pp.83-95.  Marc Better et, al. "Potent anti-CD5 ricin A chain immonconjugates from bacterially produced Fab' and F(ab')2". January 1993, Proc. Natl, Acad. Sci. USA, Vol.90, pp.457-461, Immunology.  DATE CONSIDERED	(Use se	era	l sl	heet	s i	if ne	ecessary)				U U U	<u> </u>	
FILING DATE December 5, 2001  U.S. PATENT DOCUMENT  U.S. PATENT DOCUMENT  NUMBER  DOCUMENT NUMBER  DOCUMENT NUMBER  DOCUMENT NUMBER  DOCUMENT NUMBER  DOCUMENT NUMBER  CLASS SUBCLASS  FILING DAT IF APPROPRIAT  APPROPRIAT  COUNTRY  LASS SUBCLASS  TRANSLATIO  COTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  Gavin MacBeath et,al. "Redesigning Enzyme Topology by Directed Evolution", March 20,1998, Science. Vol.279; pp.1958-1961.  Paul Carter et,al. "High Level Escherichia Coli Expression and Production of a Bivalent Humanized Antibody Fragment". February 1992, BIO/TECHNOLOGY  Vol.10, pp.163-167.  Iphigenia Leonidou Komenis et,al. "Modulating pharmacokinetics of an anti interleuken-88 (ab') 2 by amine-specific PECylation with preserved bioactivity". International J. of Pharmaceutics (2000), Vol.198, pp.83-95. Marc Better et,al. "Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2". January 1993, Proc. Natl, Acad. Sci. USA, Vol.90, pp.457-461, Immunology.  DATE CONSIDERED	8 Dire	i.						•				200	F
December 5, 2001  U.S. PATENT DOCUMENT  U.S. PATENT DOCUMENT  DOCUMENT NUMBER  DOCUMENT LASS SUBCLASS TRANSLATIO DOCUMENT SUBCLASS  TRANSLATIO DOCUMENT NUMBER  TRANSLATIO DOCUMENT NUMBER  TRANSLATIO DATE COUNTRY LASS SUBCLASS DIFFERENCE APPROPRIATION APPROPRIATION FORD APPROPRIATION APPROPRIA	1111 × 1111	7						bowdish et al.			70		<u> </u>
December 5, 2001  U.S. PATENT DOCUMENT  U.S. PATENT DOCUMENT  DOCUMENT NUMBER  DOCUMENT LASS SUBCLASS TRANSLATIO DOCUMENT SUBCLASS  TRANSLATIO DOCUMENT NUMBER  TRANSLATIO DOCUMENT NUMBER  TRANSLATIO DATE COUNTRY LASS SUBCLASS DIFFERENCE APPROPRIATION APPROPRIATION FORD APPROPRIATION APPROPRIA	م المنابع	?						FILING DATE		G	ROUS A1	t Tr	iß
U.S. PATENT DOCUMENT  OCCUMENT DATE NAME CLASS SUBCLASS IF APPROPRIATED TO COUMENTS  FOREIGN PATENT DOCUMENTS  DOCUMENT DATE COUNTRY LASS SUBCLASS TRANSLATION NUMBER  OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  Gavin MacBeath et, al. "Redesigning Enzyme Topology by Directed Evolution".  March 20,1998, Science. Vol.279, pp.1958-1961.  Paul Carter et, al. "High Level Escherichia Coli Expression and Production of a Bivalent Humanized Antibody Fragment". February 1992, BIO/TECHNOLOGY Vol.10, pp.163-167.  Iphigenia Leonidou Koumenis et, al. "Modulating pharmacokinetics of an antiinterleuken-8F(ab')2 by amine-specific PEGylation with preserved bioactivity". International J. of Pharmaceutics (2000), Vol.198, pp.83-95.  Marc Better et, al. "Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2". January 1993, Proc. Natl, Acad.  EXAMINER  DATE CONSIDERED	WAS TO ADER									16	45©°	<u> </u>	$\Gamma$
U.S. PATENT DOCUMENT INITIALS  DOCUMENT DATE NAME CLASS SUBCLASS IF APPROPRIATE  FOREIGN PATENT DOCUMENTS  DOCUMENT NUMBER  DOCUMENT DATE COUNTRY LASS SUBCLASS TRANSLATIO  TRANSLATIO  OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  Gavin MacBeath et,al. "Redesigning Enzyme Topology by Directed Evolution".  March 20,1998, Science. Vol.279, pp.1958-1961.  Paul Carter et,al. "High Level Escherichia Coli Expression and Production of a Bivalent Humanized Antibody Fragment". February 1992, BIO/TECHNOLOGY Vol.10, pp.163-167.  Iphigenia Leonidou Koumenis et,al. "Modulating pharmacokinetics of an antiinterleuken-8F(ab')2 by amine-specific PEGylation with preserved bioactivity". International J. of Pharmaceutics (2000), Vol.198, pp.83-95.  Marc Better et,al. "Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2". January 1993, Proc. Natl, Acad. Sci. USA, Vol.90, pp.457-461, Immunology.  DATE CONSIDERED								December 5, 2001			<u> </u>		E
INITIALS DOCUMENT NUMBER DATE NAME CLASS SUBCLASS IF APPROPRIATION NUMBER  FOREIGN PATENT DOCUMENTS  DOCUMENT DATE COUNTRY LASS SUBCLASS TRANSLATIO TRANSL							U	.S. PATENT DOCUMENT			<b>)</b>		(%)
POREIGN PATENT DOCUMENTS    DOCUMENT   DATE   COUNTRY   LASS SUBCLASS   TRANSLATIO	EXAMINER									1			AT!
FOREIGN PATENT DOCUMENTS  DOCUMENT DATE COUNTRY LASS SUBCLASS TRANSLATIO  OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  Gavin MacBeath et,al. "Redesigning Enzyme Topology by Directed Evolution". March 20,1998, Science. Vol.279; pp.1958-1961.  Paul Carter et,al. "High Level Escherichia Coli Expression and Production of a Bivalent Humanized Antibody Fragment". February 1992, BIO/TECHNOLOGY Vol.10, pp.163-167.  Iphigenia Leonidou Koumenis et,al. "Modulating pharmacokinetics of an anti interleuken-8F(ab')2 by amine-specific PEGylation with preserved bioactivity". International J. of Pharmaceutics (2000), Vol.198, pp.83-95.  Marc Better et,al. "Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2". January 1993, Proc. Natl, Acad. Sci. USA, Vol.90, pp.457-461, Immunology.  DATE CONSIDERED	INITIALS					`	DATE	NAME	CLASS	SUBCLA			- 3 m
DOCUMENT NUMBER  OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  Gavin MacBeath et,al. "Redesigning Enzyme Topology by Directed Evolution". March 20,1998, Science. Vol.279, pp.1958-1961.  Paul Carter et,al. "High Level Escherichia Coli Expression and Production of a Bivalent Humanized Antibody Fragment". February 1992, BIO/TECHNOLOGY Vol.10, pp.163-167.  Tphigenia Leonidou Koumenis et,al. "Modulating pharmacokinetics of an antiinterleuken-8F(ab')2 by amine-specific PEGylation with preserved bioactivity". International J. of Pharmaceutics (2000), Vol.198, pp.83-95.  Marc Better et,al. "Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2". January 1993, Proc. Natl, Acad. Sci. USA, Vol.90, pp.457-461, Immunology.  EXAMINER		Н	T N	IOMBE	T	$\overline{}$			-	+	APPI	KOPKI	.A'1
DOCUMENT NUMBER  OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  Gavin MacBeath et,al. "Redesigning Enzyme Topology by Directed Evolution". March 20,1998, Science. Vol.279, pp.1958-1961.  Paul Carter et,al. "High Level Escherichia Coli Expression and Production of a Bivalent Humanized Antibody Fragment". February 1992, BIO/TECHNOLOGY Vol.10, pp.163-167.  Tphigenia Leonidou Koumenis et,al. "Modulating pharmacokinetics of an antiinterleuken-8F(ab')2 by amine-specific PEGylation with preserved bioactivity". International J. of Pharmaceutics (2000), Vol.198, pp.83-95.  Marc Better et,al. "Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2". January 1993, Proc. Natl, Acad. Sci. USA, Vol.90, pp.457-461, Immunology.  EXAMINER		$\vdash$		t-t	十	++							
DOCUMENT NUMBER  OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  Gavin MacBeath et,al. "Redesigning Enzyme Topology by Directed Evolution". March 20,1998, Science. Vol.279, pp.1958-1961.  Paul Carter et,al. "High Level Escherichia Coli Expression and Production of a Bivalent Humanized Antibody Fragment". February 1992, BIO/TECHNOLOGY Vol.10, pp.163-167.  Tphigenia Leonidou Koumenis et,al. "Modulating pharmacokinetics of an antiinterleuken-8F(ab')2 by amine-specific PEGylation with preserved bioactivity". International J. of Pharmaceutics (2000), Vol.198, pp.83-95.  Marc Better et,al. "Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2". January 1993, Proc. Natl, Acad. Sci. USA, Vol.90, pp.457-461, Immunology.  EXAMINER		П	╅		十	$\top$	1				_		
DOCUMENT NUMBER  OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  Gavin MacBeath et,al. "Redesigning Enzyme Topology by Directed Evolution". March 20,1998, Science. Vol.279, pp.1958-1961.  Paul Carter et,al. "High Level Escherichia Coli Expression and Production of a Bivalent Humanized Antibody Fragment". February 1992, BIO/TECHNOLOGY Vol.10, pp.163-167.  Tphigenia Leonidou Koumenis et,al. "Modulating pharmacokinetics of an antiinterleuken-8F(ab')2 by amine-specific PEGylation with preserved bioactivity". International J. of Pharmaceutics (2000), Vol.198, pp.83-95.  Marc Better et,al. "Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2". January 1993, Proc. Natl, Acad. Sci. USA, Vol.90, pp.457-461, Immunology.  EXAMINER					$\perp$								
DOCUMENT NUMBER  OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  Gavin MacBeath et,al. "Redesigning Enzyme Topology by Directed Evolution". March 20,1998, Science. Vol.279, pp.1958-1961.  Paul Carter et,al. "High Level Escherichia Coli Expression and Production of a Bivalent Humanized Antibody Fragment". February 1992, BIO/TECHNOLOGY Vol.10, pp.163-167.  Tphigenia Leonidou Koumenis et,al. "Modulating pharmacokinetics of an antiinterleuken-8F(ab')2 by amine-specific PEGylation with preserved bioactivity". International J. of Pharmaceutics (2000), Vol.198, pp.83-95.  Marc Better et,al. "Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2". January 1993, Proc. Natl, Acad. Sci. USA, Vol.90, pp.457-461, Immunology.  EXAMINER													
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  Gavin MacBeath et,al. "Redesigning Enzyme Topology by Directed Evolution".  March 20,1998, Science. Vol.279; pp.1958-1961.  Paul Carter et,al. "High Level Escherichia Coli Expression and Production of a Bivalent Humanized Antibody Fragment". February 1992, BIO/TECHNOLOGY Vol.10, pp.163-167.  Iphigenia Leonidou Koumenis et,al. "Modulating pharmacokinetics of an anti interleuken-8F(ab')2 by amine-specific PEGylation with preserved bioactivity". International J. of Pharmaceutics (2000), Vol.198, pp.83-95.  Marc Better et,al. "Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2". January 1993, Proc. Natl, Acad. Sci. USA, Vol.90, pp.457-461, Immunology.  EXAMINER  DATE CONSIDERED							FOR:	EIGN PATENT DOCUMENTS					
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  Gavin MacBeath et,al. "Redesigning Enzyme Topology by Directed Evolution". March 20,1998, Science. Vol.279, pp.1958-1961.  Paul Carter et,al. "High Level Escherichia Coli Expression and Production of a Bivalent Humanized Antibody Fragment". February 1992, BIO/TECHNOLOGY Vol.10, pp.163-167.  Iphigenia Leonidou Koumenis et,al. "Modulating pharmacokinetics of an antiinterleuken-8F(ab')2 by amine-specific PEGylation with preserved bioactivity". International J. of Pharmaceutics (2000), Vol.198, pp.83-95.  Marc Better et,al. "Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2". January 1993, Proc. Natl, Acad. Sci. USA, Vol.90, pp.457-461, Immunology.  EXAMINER  DATE CONSIDERED											TRAN	SLAT	ION
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  Gavin MacBeath et,al. "Redesigning Enzyme Topology by Directed Evolution". March 20,1998, Science. Vol.279; pp.1958-1961.  Paul Carter et,al. "High Level Escherichia Coli Expression and Production of a Bivalent Humanized Antibody Fragment". February 1992, BIO/TECHNOLOGY Vol.10, pp.163-167.  Iphigenia Leonidou Koumenis et,al. "Modulating pharmacokinetics of an anti interleuken-8F(ab')2 by amine-specific PEGylation with preserved bioactivity". International J. of Pharmaceutics (2000), Vol.198, pp.83-95.  Marc Better et,al. "Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2". January 1993, Proc. Natl, Acad. Sci. USA, Vol.90, pp.457-461, Immunology.  EXAMINER			Ι				DATE	COUNTRY	LASS	SUBCLAS	s		
Gavin MacBeath et,al. "Redesigning Enzyme Topology by Directed Evolution".  March 20,1998, Science. Vol.279, pp.1958-1961.  Paul Carter et,al. "High Level Escherichia Coli Expression and Production of a Bivalent Humanized Antibody Fragment". February 1992, BIO/TECHNOLOGY Vol.10, pp.163-167.  Iphigenia Leonidou Koumenis et,al. "Modulating pharmacokinetics of an antiinterleuken-8F(ab')2 by amine-specific PEGylation with preserved bioactivity". International J. of Pharmaceutics (2000), Vol.198, pp.83-95.  Marc Better et,al. "Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2". January 1993, Proc. Natl, Acad. Sci. USA, Vol.90, pp.457-461, Immunology.  EXAMINER  DATE CONSIDERED				NUM	BEF	.₹						T	
Gavin MacBeath et,al. "Redesigning Enzyme Topology by Directed Evolution".  March 20,1998, Science. Vol.279, pp.1958-1961.  Paul Carter et,al. "High Level Escherichia Coli Expression and Production of a Bivalent Humanized Antibody Fragment". February 1992, BIO/TECHNOLOGY Vol.10, pp.163-167.  Iphigenia Leonidou Koumenis et,al. "Modulating pharmacokinetics of an antiinterleuken-8F(ab')2 by amine-specific PEGylation with preserved bioactivity". International J. of Pharmaceutics (2000), Vol.198, pp.83-95.  Marc Better et,al. "Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2". January 1993, Proc. Natl, Acad. Sci. USA, Vol.90, pp.457-461, Immunology.  EXAMINER  DATE CONSIDERED	<del></del>	+	ТТ	<del>-</del>	Т				<del></del>		+		
Gavin MacBeath et,al. "Redesigning Enzyme Topology by Directed Evolution".  March 20,1998, Science. Vol.279, pp.1958-1961.  Paul Carter et,al. "High Level Escherichia Coli Expression and Production of a Bivalent Humanized Antibody Fragment". February 1992, BIO/TECHNOLOGY Vol.10, pp.163-167.  Iphigenia Leonidou Koumenis et,al. "Modulating pharmacokinetics of an antiinterleuken-8F(ab')2 by amine-specific PEGylation with preserved bioactivity". International J. of Pharmaceutics (2000), Vol.198, pp.83-95.  Marc Better et,al. "Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2". January 1993, Proc. Natl, Acad. Sci. USA, Vol.90, pp.457-461, Immunology.  EXAMINER  DATE CONSIDERED		$\top$	$\Box$										
Gavin MacBeath et,al. "Redesigning Enzyme Topology by Directed Evolution".  March 20,1998, Science. Vol.279, pp.1958-1961.  Paul Carter et,al. "High Level Escherichia Coli Expression and Production of a Bivalent Humanized Antibody Fragment". February 1992, BIO/TECHNOLOGY Vol.10, pp.163-167.  Iphigenia Leonidou Koumenis et,al. "Modulating pharmacokinetics of an antiinterleuken-8F(ab')2 by amine-specific PEGylation with preserved bioactivity". International J. of Pharmaceutics (2000), Vol.198, pp.83-95.  Marc Better et,al. "Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2". January 1993, Proc. Natl, Acad. Sci. USA, Vol.90, pp.457-461, Immunology.  EXAMINER  DATE CONSIDERED					T						1		
Gavin MacBeath et,al. "Redesigning Enzyme Topology by Directed Evolution".  March 20,1998, Science. Vol.279, pp.1958-1961.  Paul Carter et,al. "High Level Escherichia Coli Expression and Production of a Bivalent Humanized Antibody Fragment". February 1992, BIO/TECHNOLOGY Vol.10, pp.163-167.  Iphigenia Leonidou Koumenis et,al. "Modulating pharmacokinetics of an antiinterleuken-8F(ab')2 by amine-specific PEGylation with preserved bioactivity". International J. of Pharmaceutics (2000), Vol.198, pp.83-95.  Marc Better et,al. "Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2". January 1993, Proc. Natl, Acad. Sci. USA, Vol.90, pp.457-461, Immunology.  EXAMINER  DATE CONSIDERED													
Gavin MacBeath et,al. "Redesigning Enzyme Topology by Directed Evolution".  March 20,1998, Science. Vol.279, pp.1958-1961.  Paul Carter et,al. "High Level Escherichia Coli Expression and Production of a Bivalent Humanized Antibody Fragment". February 1992, BIO/TECHNOLOGY Vol.10, pp.163-167.  Iphigenia Leonidou Koumenis et,al. "Modulating pharmacokinetics of an antiinterleuken-8F(ab')2 by amine-specific PEGylation with preserved bioactivity". International J. of Pharmaceutics (2000), Vol.198, pp.83-95.  Marc Better et,al. "Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2". January 1993, Proc. Natl, Acad. Sci. USA, Vol.90, pp.457-461, Immunology.  EXAMINER  DATE CONSIDERED	<u> </u>			Щ,	L	<u> </u>	1						
March 20,1998, Science. Vol.279, pp.1958-1961.  Paul Carter et,al. "High Level Escherichia Coli Expression and Production of a Bivalent Humanized Antibody Fragment". February 1992, BIO/TECHNOLOGY Vol.10, pp.163-167.  Iphigenia Leonidou Koumenis et,al. "Modulating pharmacokinetics of an antiinterleuken-8F(ab')2 by amine-specific PEGylation with preserved bioactivity". International J. of Pharmaceutics (2000), Vol.198, pp.83-95.  Marc Better et,al. "Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2". January 1993, Proc. Natl, Acad. Sci. USA, Vol.90, pp.457-461, Immunology.  EXAMINER  DATE CONSIDERED		OTI											
Paul Carter et,al. "High Level Escherichia Coli Expression and Production of a Bivalent Humanized Antibody Fragment". February 1992, BIO/TECHNOLOGY Vol.10, pp.163-167.  Iphigenia Leonidou Koumenis et,al. "Modulating pharmacokinetics of an antiinterleuken-8F(ab')2 by amine-specific PEGylation with preserved bioactivity". International J. of Pharmaceutics (2000), Vol.198, pp.83-95.  Marc Better et,al. "Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2". January 1993, Proc. Natl, Acad. Sci. USA, Vol.90, pp.457-461, Immunology.  EXAMINER  DATE CONSIDERED									logy by	Directe	d Evolu	ition	ı".
of a Bivalent Humanized Antibody Fragment". February 1992, BIO/TECHNOLOGY Vol.10, pp.163-167.  Iphigenia Leonidou Koumenis et,al. "Modulating pharmacokinetics of an antiinterleuken-8F(ab')2 by amine-specific PEGylation with preserved bioactivity". International J. of Pharmaceutics (2000), Vol.198, pp.83-95.  Marc Better et,al. "Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2". January 1993, Proc. Natl, Acad. Sci. USA, Vol.90, pp.457-461, Immunology.  EXAMINER  DATE CONSIDERED		$\vdash$							i Evnres	cion an	d Produ	ctic	
Vol.10, pp.163-167.  Iphigenia Leonidou Koumenis et,al. "Modulating pharmacokinetics of an antiinterleuken-8F(ab')2 by amine-specific PEGylation with preserved bioactivity". International J. of Pharmaceutics (2000), Vol.198, pp.83-95.  Marc Better et,al. "Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2". January 1993, Proc. Natl, Acad. Sci. USA, Vol.90, pp.457-461, Immunology.  EXAMINER  DATE CONSIDERED													
interleuken-8F(ab')2 by amine-specific PEGylation with preserved bioactivity". International J. of Pharmaceutics (2000), Vol.198, pp.83-95.  Marc Better et,al. "Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2". January 1993, Proc. Natl, Acad. Sci. USA, Vol.90, pp.457-461, Immunology.  EXAMINER  DATE CONSIDERED											,		
bioactivity". International J. of Pharmaceutics (2000), Vol.198, pp.83-95.  Marc Better et,al. "Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2". January 1993, Proc. Natl, Acad. Sci. USA, Vol.90, pp.457-461, Immunology.  EXAMINER  DATE CONSIDERED												n ar	ıti
Marc Better et,al. "Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2". January 1993, Proc. Natl, Acad. Sci. USA, Vol.90, pp.457-461, Immunology.  EXAMINER  DATE CONSIDERED													
bacterially produced Fab' and F(ab')2". January 1993, Proc. Natl, Acad. Sci. USA, Vol.90, pp.457-461, Immunology.  EXAMINER  DATE CONSIDERED		┝											15.
Sci. USA, Vol.90, pp.457-461, Immunology.  EXAMINER DATE CONSIDERED													
EXAMINER DATE CONSIDERED									y 1000,	rroc. N	aci, A	.aa.	
	EXAMINER					,	. <u>F</u> F -						
marageratum multiple of all all all and a considered and the constant of the c													
MPEP 609; Draw line through citation if not in conformance and not considered. Include								ation to applicant.	=======				

Form COMME OFFIC	RCE	_			-				ARTMENT OF IARK		ATTY. DOCKET NO	).				SERIAL 10 <del>/0</del> 06	
(Use	S'	TAT	EME	ENT	' B3	Α	PPI	LOSI LIC								HCENTER	
(Q) I	<b>*</b>		~0)	e A					,	1	APPLICANT Bowdish et al.					1600/2	2002
No.	ji j	8	W.	2 - 1-2 2 - 1-2							FILING DATE December 5, 200	1				OU <b>S</b> Ar	t Unit:
TO THE	<b>&gt;</b> 3:	TRE	UE,	je)					U	.S. PATE	ENT DOCUMENT						
EXAMINE	- 1				CUM				DATE		NAME		CLASS	s st	JBCLAS	s	NG DATE IF OPRIATE
	_	$\pm$	$\pm$				$\exists$										
	_			L		Н								_			
				<u></u>	<u> </u>				FOR	EIGN PAT	ENT DOCUMENTS						
			Γ						T	ſ			T			TRANS	SLATION
				Γ	NUI	JME MBE			DATE		COUNTRY		LASS	SUE	CLASS		<del></del>
			П	$\exists$	$\blacksquare$	_	Ŧ										
			Ħ		1		#	#									
			H	$\dashv$	+	+	+	+					-				
		0	THE								Title, Date, 1						
				th							"Stimulation o Igand". June 19						
				Fu	nct	io:	na:	1 J		YK2*". 1	Thrombopoietin May 7,1999, The L.						
				To Hu Er	shi mar	lo :	Kit el:	tamı l L:	ıra et,al. ine That P	"Establ rolifera	ishment and Chates Dependentl 889, J. of Cell	y on	GM_C	SF,	IL-3,	or	
				Br an	uce d 1	s '	Гуз	ros	ine Phosph	orylated	R Associates wi d and Activated Cell, Vol.74, p	fol	lowing	g St	poiet	in Rece tion w	eptor ith
EXAMIN	ER										DNSIDERED						* * * * * * * * * * * * * * * * * * * *
									<u></u>								
EXAMIN MPEP 6	ER:	I ח	nit raw	ia 1	l i	f c	it	ati	on conside	ered, wh	ether or not coin conformance	itat:	ion is	in	confo	ormance	with
											applicant.	unu	1100	.0113	ruer et	A. IIICI	.uuc

COMMERCE P	.449 PATENT A				RTMENT OF ARK				S 1	ERIAL 10/0	NO. 593
OFFICE INF	ORMATIO	N D	ISC	LOSU	IRE	54				HĈE	JUL
	TEMENT		•			·				CENTER	1 2 9
(Use seve	ral she	eets	s if	ne	cessary)						<del></del> _
anna sa						APPLICANT Bowdish et al.				1600/29	2002
48 me ii						FILING DATE			GRC 1645	UPGrt	Uniț
27						December 5, 2001					
IDADEM					υ.	.S. PATENT DOCUMENT	<u>,</u>				
EXAMINER INITIALS	DOC NU	UME MBE			DATE	NAME	CLASS	SUB	CLASS	FILIN APPRO	IF
		_	$\bot$	_			ļ			ļ	
			4	_			<b> </b>			<u> </u>	
<del></del>		-	+	+			<u> </u>			<del>                                     </del>	
					FORE	EIGN PATENT DOCUMENTS	<u> </u>			<u> </u>	
					TORE	LIGHT FAILNT DOCUMENTS					
										TRANSI	LATIO
		OCUM IUME			DATE	COUNTRY	LASS	SUBC	LASS		
					DATE	COUNTRY	LASS	SUBC	LASS		
					DATE	COUNTRY	LASS	SUBCI	LASS		
					DATE	COUNTRY	LASS	SUBC	LASS		
					DATE	COUNTRY	LASS	SUBC	LASS		
	I I	TUME	BER							c )	
	OTHER DO TIME App	OCUI Moolic	MENTOS MAI	TS (	Including Rapid Cole to Prolife: Methods"	Author, Title, Date, Per orimetric Assay for Celluration and Cytotoxicity A Vol.63, pp.5563.	rtinent ular Gro	Pages owth a	s, Et and S	urviva . of	1:
	OTHER DOTHER DOTTER DOT	OCUI Moolic nuno	MENT smarting log Ki	rs ( nn " on t ical tamu on	Including Rapid Cole to Prolife Methods" ara et,al. a factor-	Author, Title, Date, Perorimetric Assay for Cellication and Cytotoxicity 2. Vol.63, pp.5563.  "IL-1 up-regulates the edependent human hemopoies	rtinent ular Gre Assays" express	Pages owth a . (19)	;, Etand S	Surviva . of okine	
	OTHER DOTHER DOT	OCUM Modulica Muno Chio cept cept cept cept cept	MENT small log Ki ors ati	TS (mnn "ical tamu on tamu on on al	Including Rapid Cole to Prolife: Methods" ara et,al. a factor-o Immunologica et,al. a Factor-l	Author, Title, Date, Perorimetric Assay for Cellination and Cytotoxicity and Vol.63, pp.5563.  "IL-1 up-regulates the dependent human hemopoiety, Vol.3, No.6 pp.571-5"  "Identification and Anal Dependent Cell Line, TF-	ctinent ular Gre Assays" express tic cel 77.	Pages owth a . (19) ion o: l line	s, Et and S 83) J f cytt e, TF	Surviva one okine -1". (	1991;
	OTHER DOTHER DOT	OCUM Moodlic Namo Chio Cept eept .73	MENT smaati log Ki ors ati Ki ors W.	SS (mn "on tical tamu on on 2.2, Rai	Including Rapid Cole to Prolife Methods ra et,al. a factor-o tra et,al. a Factor-l pp.375-30 nes et,al	Author, Title, Date, Per orimetric Assay for Celli ration and Cytotoxicity 2. Vol.63, pp.5563.  "IL-1 up-regulates the edependent human hemopoie gy, Vol.3, No.6 pp.571-5"  "Identification and Anal Dependent Cell Line, TF-180 "Purification of Human	express tic cellary. The service of	Pages owth a . (198 ion or l line f Humaruary	s, Et and S 83) J f cyt e, TF an Er 1989	Surviva One	1991 ooiet:
EXAMINER	OTHER DOTHER DOT	OCUM Moodlic Namo Chio Cept eept .73	MENT smaati log Ki ors ati Ki ors W.	SS (mn "on tical tamu on on 2.2, Rai	Including Rapid Cole to Prolife Methods ra et,al. a factor-o tra et,al. a Factor-l pp.375-30 nes et,al	Author, Title, Date, Perorimetric Assay for Cellination and Cytotoxicity 2. Vol.63, pp.5563.  "IL-1 up-regulates the dependent human hemopoietgy, Vol.3, No.6 pp.571-5"  "Identification and Anal Dependent Cell Line, TF-180.	express tic cellary. The service of	Pages owth a . (198 ion or l line f Humaruary	s, Et and S 83) J f cyt e, TF an Er 1989	Surviva One	1991; ooiet:

copy of this form with next communication to applicant.

Form PTC		-				PARTMENT OF EMARK					ER <b>LA</b> L .0 <b>/10</b> 06	, 593 🛌
OFFICE							54					
I	NFORI	1AT	ION	DIS	SCLO	SURE					CEN	של חר
S	TATE	1EN'	r By	Y AI	PPLI	CANT						200 IT
(IIse se	vera	1 c	hee	ts	ifi	necessary)					500	9 11
7.7 E	<u> </u>		1100			iccepbary,	APPLICANT				1500/	<b>20</b>
\Q_*		\					Bowdish et al.				0/29	
/	uas ,	벍					FILING DATE		1	CBO	U <b>S</b> Art	<del>- IIni</del> D
19 7 JUL 19 7	- سر	Ī.					FIDING DATE			1645		, Unite.
13		<u>7                                    </u>					December 5, 2001					
TOAD!	E. Militar					U	.S. PATENT DOCUMENT					
EXAMINER	Ì	_			_						1	IG DATE
INITIALS			AUME		Ľ	DATE	NAME	CLASS	SUBC	CLASS		IF OPRIATE
	$\top$	T	1				· · · · · · · · · · · · · · · · · · ·	<u> </u>	1.		ALTIC	/I ILIAID
	$+\!+$	4	┿	Н	4		994	ļ				
	+	-	+-	╀┼	_							
					Щ.	J FOR	EIGN PATENT DOCUMENTS	<u> </u>				
			DOC!	UMEI MBEI		DATE	COUNTRY	LASS	SUBCL	ASS	TRANS	LATION
				1							-	
	_	-	4	$\perp$	$\sqcup$		The state of the s				<del></del>	
		$\vdash$	-		${}^{+}$	<u> </u>				$-\!\!+$		
			+	+	${}^{\dag}$					$\dashv$	<del></del>	<del> </del>
	ОТН	ER	DOC	UME	NTS	(Including	Author, Title, Date, Per	tinent	Pages	, Et	c.)	——
		M	lari	a A	. De	eBernardi et	,al. "Single cell Ca2+/c	AMP cro	ss-ta	lk mo	nitor	
							P fluor escence ratio ima		May 1	<del>9</del> 96,	Proc.	Natl.
	-						3, pp.4577-4582, Cell Bio "Signaling Through the H		ietic	Cyto	rkine	
		F	ece	pto	rs"	. (1995), Ar	nnu. Rev. Immunology, Vol	.13, pp	369-	398.	XIIIC	
		C	J.	Ea	ves	"Assays of	Hemopoietic Progenitor C	ells".	Willia	ams F	Iemato:	logy,
	-						4, pp.L22-L26.	<del></del>	•			
		V	onn 'ivo	r.	Cai June	rison et,al. e 1988. Mole	"Molecular Tools for In ecular and Cellular Biolo	activat gv. Vol	ing a	Yeas ۲ م. د	on 264	yme In 7-2650
EXAMINER		<u>, , , , , , , , , , , , , , , , , , , </u>	_,,	•			DATE CONSIDERED	<u> </u>	, 110	<u>,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,</u>	<u>~~.20∓</u>	. 2030.
EVAMINED.	Tni	+:-	1 :	f ~	i + ~ ·	tion conside	ered, whether or not cita	tion 3				
MPEP 609;	Dra	w ]	ine.	th	rou	gh citation	if not in conformance an	d not a	onside	onioi ered	mance . Incl	with ude
copy of t	his	for	m w	ith	ne	xt communica	ation to applicant.					

COMMERCE I	1449 PATEN					ARTMENT OF MARK	ATTY. DOCKET NO.				ERIAL NO.
OFFICE							74				
STA	FORMAT ATEMEN	NT B	BY.	API	PLIC	ANT					ER 1600/29)
Ose seve	eral_	she	et:	s i	f n	ecessary)					22
JUL 1 9 200	5						APPLICANT Bowdish et al.				8
	TO I						FILING DATE			1	UP Art Unit
<u> </u>	<u>;</u> 5						December 5, 2001			1645	•
						II	.S. PATENT DOCUMENT				
XAMINER NITIALS	I	DOCU NUM				DATE	NAME	CLASS	SUB	CLASS	FILING DAT
		$\Box$	I	I	П						
		+	+	╀	++						
		士	土	土	廿						
			$\perp$	丄	Ш	FOR	DION DAMENT DOGUMENTO	<u></u>			
						FOR	EIGN PATENT DOCUMENTS				
				IEN' BER	r	DATE	COUNTRY	LASS	SUBC	LASS	TRANSLATION
	扛	П		П	$\Box$						
		$\square$	_	$\vdash$	4						
	++	+	$\dashv$	H	+			+			
				$\Box$	工						
	$\bot$		CUI				Author, Title, Date, Per				
		Johi	n J				"Production of monoclonal				
		Johi cel: Andi	n 3 ls' rev	″. w H	(19 iat	95), Current et,al. "1	"Production of monoclonal nt Opinion in Biotechnolo Production of antibodies re, Vol.342, pp76-78.	gy, Vol.	6 pr	5.553-	-560.
		John cel: And Nove L. S	n J ls' rew emb Sta tei	w H ber anf	iat 2, ord Cor	95), Current et,al. "1 1989, Natur Lee et,al njugation (	nt Opinion in Biotechnolo Production of antibodies	gy, Vol. in trans Lives of	6 pr geni Sir	c pla	.560. nnts". Chain Fv

of this form with next communication to applicant.